Jeanne Bolger

Calypso Biotech is a biopharmaceuticals company that discovers and develops novel therapies for auto-immune diseases.

S-Biomedic is a life science company focused on skin health by pioneering the development of Pro- and Post-biotic ingredients from true skin commensals. S-Biomedic delivers: • novel active ingredients for use in cosmetic formulations • unique positioning & skin benefits • clinically substantiated efficacy claims S-Biomedic is changing the paradigm in skincare and dermatology by unleashing the natural power of your skin microbiome capitalizing on its breakthrough proprietary technology platform and expertise to deliver novel solutions for a wide variety of skin conditions. S-Biomedic is changing the paradigm in skincare and dermatology by unleashing the natural power of your skin microbiome capitalizing on its breakthrough proprietary technology platform and expertise to deliver novel solutions for a wide variety of skin conditions.

Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders. Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com. Further information: www.asceneuron.com

AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen.

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs with a focus in oncology, and expanding its test menu in infectious diseases with partners. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis’ vision is to enable personalized medicine for patients around the world through universal access to molecular testing. Our mission is to make molecular testing actionable, convenient, fast and suitable for any lab. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com

Investing in life sciences. Investing in life. Seroba is a European life sciences venture capital firm based in Dublin, Paris and Milan, investing its fourth Fund. We focus on value creation through backing cutting-edge biotech and medtech innovation that will transform the treatment of unmet medical needs. Our team has deep industry and operational experience and an extensive global network. We like to work with entrepreneurs who share our passion for success and for investors who share the same goal of improving human health while driving financial returns.

Calypso Biotech is a biopharmaceuticals company that discovers and develops novel therapies for auto-immune diseases.

S-Biomedic is a life science company focused on skin health by pioneering the development of Pro- and Post-biotic ingredients from true skin commensals. S-Biomedic delivers: • novel active ingredients for use in cosmetic formulations • unique positioning & skin benefits • clinically substantiated efficacy claims S-Biomedic is changing the paradigm in skincare and dermatology by unleashing the natural power of your skin microbiome capitalizing on its breakthrough proprietary technology platform and expertise to deliver novel solutions for a wide variety of skin conditions. S-Biomedic is changing the paradigm in skincare and dermatology by unleashing the natural power of your skin microbiome capitalizing on its breakthrough proprietary technology platform and expertise to deliver novel solutions for a wide variety of skin conditions.

Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders. Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com. Further information: www.asceneuron.com

AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen.